Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31467198 | 0.95 | SLC6A5 (0.56) | SLC6A5NMT2NMT1KMT2APOLB | |
| SCHEMBL13745591 | 0.91 | SLC6A5 (0.43) | SLC6A5NMT2NMT1KMT2APOLB | |
| SCHEMBL28698069 | 0.91 | SLC6A5 (0.62) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL18796595 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL3174603 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL18796577 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL8620977 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL8015737 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL8015739 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 | |
| SCHEMBL28476515 | 0.90 | SLC6A5 (0.64) | SLC6A5NMT2NMT1KMT2AERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |